In order to place your biocidal products on the market, you must comply with numerous regulations, such as the Biocidal Products Regulation (EU) No. 528/2012 (BPR). This includes the regulation of the active substances that can be used and the approved active substance suppliers as well as the labelling and marking of biocidal products and treated articles.
From biocidal product authorisation to active substance approval, we work with you to develop a strategy tailored to your product portfolio and market requirements and support you in its implementation.
When it comes to biocides and the associated legislation and regulations, we are the experts at your side.
"The complexity of the Biocides Regulation poses a considerable challenge for many companies. With our in-depth expertise and clear, focussed communication, we accompany you step by step. Your compliance is not just our goal, it is our shared mission."
Kai Dettmer | Biocide expert
"When working with UMCO, we can say that the chemistry was always right in the truest sense of the word. Throughout the entire project, UMCO was available to us as a competent consultant. They took a detailed look at our data situation and successfully met all regulatory challenges, always meeting all official deadlines. Our discussions with UMCO were always on an equal footing, resulting in close and constructive communication.
Particularly noteworthy is the overall package of services offered by UMCO, from hazardous substances law and biocide law to toxicological evaluations, etc., combined with comprehensive flexibility in all specialist areas. We at Tetra GmbH recommend UMCO at any time."
Biocide team | Tetra GmbH
The Biocidal Products Regulation (EU) No. 528/2012 was adopted in 2012 to harmonise the use and placing on the market of biocidal products within the European Union. The Biocidal Products Regulation replaces the Biocidal Products Directive (98/8/EC). Since Brexit, the Great Britain BPR, which regulates the requirements for biocidal products and biocidal active substances in Great Britain and Northern Ireland, has existed in parallel to the EU BPR.
In the Regulation on the review programme (EU) No. 1062/2014, the term "existing active substances" describes those active substances that were already used as active substances in biocidal products and marketed for commercial purposes on 14 May 2000. If a corresponding notification and an active substance dossier have been submitted for these substances, the existing active substance is then evaluated by the member states and the ECHA and, ideally, approved. Theoretically, all existing active substances should be finally evaluated by 2024, although it is already becoming apparent that this deadline will be extended.
Existing active substances in the review programme can benefit from the transitional measures described in Article 89 of the BPR. This means that biocidal products with at least one existing active substance that is still under review can be placed on the market without a biocidal product authorisation under the BPR. However, the national regulations and, where applicable, notification requirements of the respective member state must be complied with.
If all existing active substances in a product are approved or if this product contains approved new active substances, an authorisation procedure specified in the Biocidal Products Ordinance must be followed. For this purpose, a complete product dossier must be submitted that fulfils the data requirements of the BPR. Depending on the product and the planned marketing, different types of authorization can be applied for. For active substances listed in Annex I of the BPR, a simplified authorisation procedure can also be used.
Instead of individual biocidal products, biocidal product families can also be authorized. These consist of a grouping of products that are all used for the same purpose and contain the same active substances. The composition of non-active substances can vary slightly between the different members of the family. For example, antimicrobial paints can be assessed as a biocidal product family if they differ only in their colour shades and therefore have a slightly varying composition due to different colourants.
Authorised suppliers of active substances are included in the list in accordance with Article 95 of the Biocidal Products Regulation. Since 1 September 2015, biocidal products have only been permitted on the EU market under the Biocidal Products Regulation if the respective product or active substance supplier, manufacturer or distributor is included on the list in accordance with Article 95. In order to be included on the list as a legal entity, a letter of access to the respective active substance dossier must generally be submitted. As a result of Brexit and the introduction of the UK BPR, a separate UK Article 95 list now exists for the UK market.
The Biocidal Products Ordinance also regulates the provision and use of goods that have been treated with biocidal products or contain them, for example in the form of preservatives. Special provisions apply to the labelling of treated goods in accordance with Article 58 of the Biocidal Products Regulation.
Jan Mönster
Do you have any questions about our company? Please give me a call!
Phone: +49 40 555 546 360
Email: vertrieb@umco.de
We use cookies to give you the best possible experience on our website and to improve our communication with you. We take your choices into account and only use the data for which you give us your consent.
Here you will find an overview of all categories. You can select your consent to individual categories.
These cookies help to make our website usable by enabling basic functions such as page navigation and access to secure areas. Our website cannot function properly without these cookies.
These cookies help us to understand how visitors interact with our website by collecting information anonymously. With this information we can continuously improve our offer.
These cookies are used to follow visitors on websites. The intention is to show adverts that are relevant and engaging to the individual user and therefore more valuable to publishers and third party advertisers.